Risankizumab

ApprovedCompleted

0 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Inflammatory Bowel Disease

Conditions

Inflammatory Bowel Disease

Trial Timeline

Apr 24, 2024 → Feb 5, 2026

NCT ID

NCT06346288

About Risankizumab

Risankizumab is a approved stage product being developed by AbbVie for Inflammatory Bowel Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT06346288. Target conditions include Inflammatory Bowel Disease.

What happened to similar drugs?

9 of 20 similar drugs in Inflammatory Bowel Disease were approved

Approved (9) Terminated (3) Active (11)

✅Infliximab + Infliximab + InfliximabCelltrionApproved

✅fidaxomicinAstellas PharmaApproved

✅Human Papillomavirus VaccineMerckApproved

✅BezlotoxumabMerckApproved

✅Celecoxib + Ibuprofen plus OmeprazolePfizerApproved

✅Alemtuzumab infusionSanofiApproved

✅IgPro10CSLApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (15)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03914261	Pre-clinical	Completed	—	—	Crohn's Disease
NCT06946524	Phase 1	Completed	May 8, 2025	Nov 25, 2025	Healthy Volunteers
NCT06937619	Phase 1	Completed	Apr 21, 2025	Nov 10, 2025	Healthy Volunteer
NCT06571266	Phase 1	Completed	Sep 11, 2024	Apr 16, 2025	Healthy Volunteers
NCT06346288	Approved	Completed	Apr 24, 2024	Feb 5, 2026	Inflammatory Bowel Disease
NCT06054425	Phase 1	Completed	Nov 20, 2023	May 6, 2024	Healthy Volunteers
NCT05283135	Phase 2	Completed	Mar 1, 2022	Jul 10, 2024	Psoriasis
NCT04862286	Phase 3	Active	Jul 24, 2021	Apr 1, 2028	Psoriasis
NCT05274087	Phase 1	Completed	Sep 15, 2020	Apr 7, 2021	Healthy Volunteers
NCT04102007	Phase 3	Completed	Nov 12, 2019	Nov 7, 2022	Plaque Psoriasis
NCT03875508	Phase 3	Completed	Jun 4, 2019	Aug 25, 2020	Psoriasis
NCT03047395	Phase 3	Completed	Feb 27, 2017	Nov 29, 2023	Psoriasis
NCT03022045	Phase 3	Completed	Jan 26, 2017	Nov 19, 2020	Psoriasis
NCT02986373	Phase 2	Completed	Dec 15, 2016	Jul 30, 2018	Psoriatic Arthritis
NCT02203851	Phase 2	Completed	Nov 20, 2014	Sep 4, 2018	Psoriasis

Competing Products

20 competing products in Inflammatory Bowel Disease

See all competitors

Product	Company	Stage	Hype Score
Infliximab + Infliximab + Infliximab	Celltrion	Approved	50
CT-P13	Celltrion	Phase 3	36
Subcutaneous infliximab CT-P13 Remsima®SC	Celltrion	Pre-clinical	22
Infliximab subcutaneous + Immunosuppressive Agents	Celltrion	Phase 3	47
fidaxomicin	Astellas Pharma	Approved	43
Eribulin + Adriamycin + Cyclophosphamide	Eisai	Phase 2	39
E6007 + E6007 + E6007 + E6007 + E6007 + E6007	Eisai	Phase 1	29
Placebo + MORF-057	Eli Lilly	Phase 2	42
Baricitinib + Baricitinib	Eli Lilly	Phase 2	35
LY3114062 SC + Placebo + LY3114062 IV	Eli Lilly	Phase 1	29
MORF-057 + Placebo	Eli Lilly	Phase 2	39
MORF-057	Eli Lilly	Phase 2	35
LY3009104	Eli Lilly	Phase 1	29
HRF2105 patch + Loxoprofen patch + placebo	Jiangsu Hengrui Medicine	Phase 2	31
GC012F Injection infusion	AstraZeneca	Phase 1	36
AZD6793 + Placebo	AstraZeneca	Phase 1	29
Human Papillomavirus Vaccine	Merck	Approved	43
Pembrolizumab	Merck	Phase 2	31
Gardasil vaccine	Merck	Pre-clinical	26
Bezlotoxumab	Merck	Approved	35